Cyclic peptides open new drug frontiers, if manufacturing can keep up

Summary

Viva Biotech's experts discussed how cyclic peptides represent a promising therapeutic modality combining small molecule convenience with antibody-like selectivity, though manufacturing challenges and bioavailability limitations remain barriers to broader development. The company outlined hybrid synthesis, ADME/PK modeling, and AI-guided design approaches to advance cyclic peptide therapeutics.